Adaptimmune Therapeutics shares are trading higher after the company and Galapagos entered a clinical collaboration to license Adaptimmune's uza-cel in in head & neck cancer.
Portfolio Pulse from Benzinga Newsdesk
Adaptimmune Therapeutics shares are trading higher after the company and Galapagos entered a clinical collaboration to license Adaptimmune's uza-cel in head & neck cancer.
May 31, 2024 | 11:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptimmune Therapeutics shares are trading higher following a clinical collaboration with Galapagos to license Adaptimmune's uza-cel for head & neck cancer treatment.
The collaboration with Galapagos to license uza-cel for head & neck cancer is a significant development for Adaptimmune Therapeutics, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100